Navigation Links
Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease
Date:3/10/2011

PHILADELPHIA, March 10, 2011 /PRNewswire/ -- On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased to announce its renewed commitment, hope and support for the worldwide maintenance of healthy kidney function among all those people with kidney problems.

In addition, Kibow Biotech, Inc. would also like to announce that it has received Institutional Review Board (IRB) approvals for conducting human clinical trials with its patented, proprietary and probiotic dietary supplement product – Kibow® Biotics. These human clinical trials will soon be initiated on dialysis patients at Thomas Jefferson University in Philadelphia, PA and the State University of New York (Downstate Medical Center & King's County Hospital, in Brooklyn, NY). Further IRB approval at The Mayo Clinic in Rochester, MN is pending for Chronic Kidney Disease (CKD) III & IV patients.

The Company's novel probiotic dietary supplement product, Kibow® Biotics, utilizes a patented and proprietary bowel-based uremic toxin reduction technology for use in clinical applications towards maintaining a healthy kidney function. Kibow® Biotics has three probiotic microbial strains that are Generally Recognized As Safe (GRAS) by the U.S. FDA. This status essentially means that Kibow® Biotics is generally known, among skilled scientific and medical experts, as having been adequately shown to be safe under the conditions of its intended use.

Dr. Ranganathan states, "By developing an affordable, readily available and easy-to-administer dietary supplement, Kibow offers hope to all those who suffer from kidney problems in the USA and other countries, while in accordance with their respective governmental regulatory/registration authorities."

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow® Biotics," an orally consumable, enteric-coated capsule formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

About Chronic Kidney Disease (CKD)According to the National Kidney Foundation, more than 26 million Americans - one in nine adults - have kidney disease and most don't know it. Since kidney disease is often silent without any symptoms, it can go undiagnosed, especially in those who are not aware of the major risk factors. Anyone with high blood pressure, diabetes or a family history of these conditions or kidney disease is at risk and should get his or her kidneys checked. Kidney disease can be found and treated early to prevent more serious kidney disease and other complications.

Forward-looking statements:

Kibow® Biotics or any other dietary supplements are not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to: the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information:Natarajan Ranganathan, Ph.D.CEO and Senior VP (R&D)Tel: (610) 353-5130Toll Free: 1-888-271-2560info@kibowbiotech.com Website: http://www.kibow.com Facebook: http://www.facebook.com/kibowbiotech YouTube: http://www.youtube.com/kibowbiotech This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
2. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
3. Thomson Reuters Launches Academic Reputation Survey as Part of Global Institutional Profiles Project
4. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
5. Schulman Associates IRB Establishes an Institutional Review Board in Canada
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
10. AEterna Zentaris Receives US$10 Million from Institutional Investors
11. NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom ... North American hospitals, will present its chain-of-custody solution for tracking and securing medications ... Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for tracking ...
(Date:12/2/2016)... ... December 02, 2016 , ... The ... to collaboratively developing improved chemistry, manufacturing and control technologies for the pharmaceutical ... with robust, probe-based sampling. , Online liquid chromatography analysis is becoming ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... new moving magnet Voice Coil Actuator with a flexure design that ensures high ... life with cost-effective pricing and is ideally suited where extreme precision is required, ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen ... Cell Collection: the first publicly available collection of ... cells that target key cellular structures with unprecedented ... Research, these powerful tools are a crucial first ... to better understand what makes human cells healthy ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):